Tenofovir alafenamide for treating chronic hepatitis B infection

Liver

Infections

18 January 2021

Published on 18 Jan 2021
Last Updated on 18 Jan 2021

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended listing tenofovir alafenamide (TAF) on the Medication Assistance Fund (MAF) for treating chronic hepatitis B infection, due to unfavourable cost-effectiveness compared with tenofovir disoproxil fumarate (TDF) at the price proposed by the manufacturer.

Tenofovir alafenamide for treating chronic hepatitis B infection (18 Jan 2021) [PDF, 46 KB]